Paradigm BioCapital reports 9.5% stake in Edgewise Therapeutics (EWTX) common stock

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. has a significant shareholder group led by Paradigm BioCapital entities and Senai Asefaw, M.D., reporting beneficial ownership of the company’s common stock as of June 30, 2026. Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, and Senai Asefaw may each be deemed to beneficially own 10,215,455 shares of common stock, representing 9.5% of the class, based on 107,593,006 shares outstanding as of April 30, 2026.

Paradigm BioCapital International Fund Ltd. directly holds 8,961,631 shares, or 8.3% of the common stock, with additional shares held in one or more separately managed accounts advised by Paradigm BioCapital Advisors LP. Each reporting party has sole voting and dispositive power over its reported shares and disclaims beneficial ownership of any shares beyond those directly held.

Key Figures

Shares beneficially owned (Adviser group): 10,215,455 shares Ownership percentage (Adviser group): 9.5% Shares beneficially owned (Fund): 8,961,631 shares +2 more

5 metrics

Shares beneficially owned (Adviser group) 10,215,455 shares Beneficial ownership reported by Paradigm BioCapital Advisors LP, its GP, and Senai Asefaw

Ownership percentage (Adviser group) 9.5% Percent of Edgewise Therapeutics common stock class

Shares beneficially owned (Fund) 8,961,631 shares Direct holdings of Paradigm BioCapital International Fund Ltd.

Ownership percentage (Fund) 8.3% Percent of Edgewise Therapeutics common stock class held by the Fund

Shares outstanding 107,593,006 shares Common stock outstanding as of April 30, 2026, used to calculate ownership percentages

Key Terms

beneficially own, sole voting power, sole dispositive power, separately managed accounts, +1 more

5 terms

beneficially own financial

"The Fund and one or more separately managed accounts managed by the Adviser ... directly beneficially own the Common Stock"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole voting power financial

"Sole Voting Power 10,215,455.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 10,215,455.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

separately managed accounts financial

"The Fund and one or more separately managed accounts managed by the Adviser (the "Account")"

A separately managed account is an investment portfolio owned by a single investor but professionally managed to that investor’s specific goals and preferences, rather than pooled with other clients’ money. It matters to investors because it offers greater customization, tax control and transparency—like hiring a personal chef instead of eating from a shared buffet—though it often requires higher minimums and can have different fee and liquidity implications.

percent of class financial

"Percent of class: See Item 11 on the cover page for each Reporting Person."

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

How much of Edgewise Therapeutics (EWTX) does Paradigm BioCapital report owning?

Paradigm BioCapital Advisors LP, its GP, and Senai Asefaw collectively report beneficial ownership of 10,215,455 shares of Edgewise Therapeutics common stock, representing 9.5% of the outstanding class, based on 107,593,006 shares outstanding as of April 30, 2026.

What stake in Edgewise Therapeutics (EWTX) is held by Paradigm BioCapital International Fund Ltd.?

Paradigm BioCapital International Fund Ltd. directly holds 8,961,631 shares of Edgewise Therapeutics common stock, representing 8.3% of the class, with sole voting and dispositive power over these shares as reported.

On what share count is Paradigm BioCapital’s EWTX ownership percentage based?

The reported ownership percentages are based on 107,593,006 shares of Edgewise Therapeutics common stock outstanding as of April 30, 2026, as reported by the company in its Form 10-Q filed on May 7, 2026.

Who are the reporting persons for the Edgewise Therapeutics (EWTX) ownership disclosure?

The reporting persons are Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., including the adviser, its general partner, an individual manager, and a Cayman Islands fund.

What voting and dispositive powers do Paradigm BioCapital entities report over EWTX shares?

The Paradigm entities and Senai Asefaw each report sole voting power and sole dispositive power over 10,215,455 shares, while the Fund separately reports sole voting and dispositive power over 8,961,631 shares, with no shared powers disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:28 PM Accepted by SEC EDGAR 08/14/2026 - 04:22 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Edgewise Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

28036F105

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 28036F105

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 10,215,455.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,215,455.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,215,455.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.5 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 28036F105

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 10,215,455.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,215,455.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,215,455.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.5 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP Number(s): 28036F105

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 10,215,455.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,215,455.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,215,455.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 28036F105

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,961,631.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,961,631.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,961,631.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.3 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Edgewise Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1715 38th Street, Boulder, CO 80301
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 520 Fifth Avenue, 23rd Floor, New York, NY 10036.
(c)	Citizenship: For citizenship or place of origin see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 28036F105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on June 30, 2026, the Date of Event which requires the filing of this Schedule 13G.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 107,593,006 shares of Common Stock outstanding as of April 30, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on May 7, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	08/14/2026

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	08/14/2026

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	08/14/2026

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	08/14/2026